Amicus Therapeutics
FOLD
$10.47
Share price
1.85%
Change (1 day)
-9.27%
Change (1 year)
Categories
Amicus Therapeutics (FOLD) - Cash on Hand
Cash on Hand as of December 2023 : $0.28 B
According to Amicus Therapeutics
's latest financial reports the company has $0.28 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Amicus Therapeutics - Cash on Hand chart (from 2005 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.28 B | -2.52% |
| 2022-12-31 | $0.29 B | -39.15% |
| 2021-12-31 | $0.48 B | -0.16% |
| 2020-12-31 | $0.48 B | 6.74% |
| 2019-12-31 | $0.45 B | -10.2% |
| 2018-12-31 | $0.50 B | 40.6% |
| 2017-12-31 | $0.35 B | 8.54% |
| 2016-12-31 | $0.33 B | 54.35% |
| 2015-12-31 | $0.21 B | 41.11% |
| 2014-12-31 | $0.15 B | 84.97% |
| 2013-12-31 | $82 M | -17.27% |
| 2012-12-31 | $99.12 M | 77.95% |
| 2011-12-31 | $55.7 M | -48.16% |
| 2010-12-31 | $0.10 B | 37.36% |
| 2009-12-31 | $78.22 M | -35.42% |
| 2008-12-31 | $0.12 B | -25.01% |
| 2007-12-31 | $0.16 B | 195.3% |
| 2006-12-31 | $54.69 M | 124.01% |
| 2005-12-31 | $24.41 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novo Nordisk NVO | $4.47 B | 1,464.34% | 🇩🇰 Denmark |
 Biogen BIIB | $1.07 B | 275.40% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $6.35 B | 2,120.41% | 🇬🇧 UK |
 Lexicon Pharmaceuticals
LXRX | $0.17 B | -40.59% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | $82.24 M | -71.26% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.07 B | 275.20% | 🇺🇸 USA |